Briefly, the miR-216a-expressing group had a lower number of tumour foci in the lungs than the control group, whereas the miR-216a plus CDK14 group displayed reversal of the effects of miR-216a on the metastatic foci. The gene discussed is CDK14; the disease is neoplasm.